Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials
ABSTRACT Background Cancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence‐free survival (RFS) or disease‐free survival (DFS) specifically predict overall survival (OS) in resectable esophageal cancer (EC). Methods A systematic literature review identified trials w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763236341088256 |
|---|---|
| author | Uchechukwu Love Anyaduba Oluwatosin Qawiyy Orababa Zion Faye Nazia Rashid Jason Shafrin Gregory Reardon |
| author_facet | Uchechukwu Love Anyaduba Oluwatosin Qawiyy Orababa Zion Faye Nazia Rashid Jason Shafrin Gregory Reardon |
| author_sort | Uchechukwu Love Anyaduba |
| collection | DOAJ |
| description | ABSTRACT Background Cancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence‐free survival (RFS) or disease‐free survival (DFS) specifically predict overall survival (OS) in resectable esophageal cancer (EC). Methods A systematic literature review identified trials with RFS/DFS and OS endpoints. A meta‐analysis assessed RFS/DFS as surrogates for OS, estimating pooled hazard ratios (HRs) from trial HRs. Forest plots and heterogeneity tests showed effect sizes and pooled estimates. Unweighted linear regression and weighted sensitivity analysis estimated the correlation between OS and RFS/DFS, producing a regression plot. Results Of 975 articles identified, 11 met the criteria. The pooled HR for OS and RFS/DFS was 0.90 and 0.87, respectively. The primary analysis showed a strong Pearson correlation between RFS/DFS and OS (ρ = 0.89, p < 0.001). Conclusion Subject to known methodological limits, RFS/DFS was demonstrated to be a potentially suitable surrogate endpoint for OS in resectable EC. |
| format | Article |
| id | doaj-art-4d8452cfd63e4aa9a5471eabcbf81332 |
| institution | DOAJ |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-4d8452cfd63e4aa9a5471eabcbf813322025-08-20T03:05:27ZengWileyCancer Reports2573-83482025-05-0185n/an/a10.1002/cnr2.70195Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer TrialsUchechukwu Love Anyaduba0Oluwatosin Qawiyy Orababa1Zion Faye2Nazia Rashid3Jason Shafrin4Gregory Reardon5Henry E. Riggs School of Applied Life Sciences Keck Graduate Institute Claremont California USASchool of Life Sciences, Gibbet Hill Campus University of Warwick Coventry UKHenry E. Riggs School of Applied Life Sciences Keck Graduate Institute Claremont California USASchool of Pharmacy Keck Graduate Institute Claremont California USACenter for Healthcare Economics and Policy FTI Consulting Los Angeles California USASchool of Pharmacy Keck Graduate Institute Claremont California USAABSTRACT Background Cancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence‐free survival (RFS) or disease‐free survival (DFS) specifically predict overall survival (OS) in resectable esophageal cancer (EC). Methods A systematic literature review identified trials with RFS/DFS and OS endpoints. A meta‐analysis assessed RFS/DFS as surrogates for OS, estimating pooled hazard ratios (HRs) from trial HRs. Forest plots and heterogeneity tests showed effect sizes and pooled estimates. Unweighted linear regression and weighted sensitivity analysis estimated the correlation between OS and RFS/DFS, producing a regression plot. Results Of 975 articles identified, 11 met the criteria. The pooled HR for OS and RFS/DFS was 0.90 and 0.87, respectively. The primary analysis showed a strong Pearson correlation between RFS/DFS and OS (ρ = 0.89, p < 0.001). Conclusion Subject to known methodological limits, RFS/DFS was demonstrated to be a potentially suitable surrogate endpoint for OS in resectable EC.https://doi.org/10.1002/cnr2.70195disease‐free survivalesophageal canceresophageal neoplasmslocalneoplasm recurrencerandomized controlled trial |
| spellingShingle | Uchechukwu Love Anyaduba Oluwatosin Qawiyy Orababa Zion Faye Nazia Rashid Jason Shafrin Gregory Reardon Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials Cancer Reports disease‐free survival esophageal cancer esophageal neoplasms local neoplasm recurrence randomized controlled trial |
| title | Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials |
| title_full | Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials |
| title_fullStr | Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials |
| title_full_unstemmed | Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials |
| title_short | Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials |
| title_sort | meta analysis of recurrence free survival or disease free survival as a potential surrogate endpoint for overall survival in esophageal cancer trials |
| topic | disease‐free survival esophageal cancer esophageal neoplasms local neoplasm recurrence randomized controlled trial |
| url | https://doi.org/10.1002/cnr2.70195 |
| work_keys_str_mv | AT uchechukwuloveanyaduba metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials AT oluwatosinqawiyyorababa metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials AT zionfaye metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials AT naziarashid metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials AT jasonshafrin metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials AT gregoryreardon metaanalysisofrecurrencefreesurvivalordiseasefreesurvivalasapotentialsurrogateendpointforoverallsurvivalinesophagealcancertrials |